Patients with rheumatoidarthritis treated with tofacitinib were 69% less likely to develop ILD, compared with those treated with adalimumab, according to a new retrospective study. RheumTwitter RA
, researchers used the Optum Clinformatics Data Mart to identify claims data for patients with RA who were taking b/tsDMARDs from December 2003 to December 2019. Patients were excluded if they had a preexisting diagnosis of ILD or if they had less than 1 year of continuous enrollment in the data set.
"Patients who generally looked similar with RA, but were given different treatments, had different risks of developing ILD," Baker said."Based on what we found, most of the biologic therapies had similar rates of developing ILD, but the JAK inhibitor tofacitinib had a reduced risk." Additional research is necessary to see if tofacitinib shows the same benefit in prospective studies, he said.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Study: Beethoven Hair Auctioned for Thousands May Not All Be HisHair samples believed to be from Ludwig van Beethoven that were auctioned for high prices might not actually be his, according to DNA testing.
Weiterlesen »
Thai PM Prayuth to run for re-election in MayThailand's Prime Minister Prayuth Chan-ocha was officially nominated for re-election on Saturday as his party's first candidate for the country's next leader in polls set for May 14.
Weiterlesen »
27 Things From Amazon With Such Great Reviews, You May Want To Own Them Yourself10/10 need all of this.
Weiterlesen »
Why there may be no return to 'normal' for the U.S. used vehicle marketA notable decline in used vehicle prices toward the end of last year has been roughly cut in half in 2023, as inventories remain lower and prices are high.
Weiterlesen »
You may owe taxes on your crypto investments — here are 3 things to knowTax season can be a complicated time for cryptocurrency investors. Here are three things to know.
Weiterlesen »